Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Organon & Co. Common Stock — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $14.18 (market cap $1.14B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 3.2× YieldMax MSTR Option Income Strategy ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while YieldMax MSTR Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax MSTR Option Income Strategy ETF for 31 Days and Organon & Co. Common Stock for 0 Days on average.
| MSTY | OGN | |
|---|---|---|
Market Cap | $1.14B | $3.62B |
Volume | 1,611,783 | 2,892,999 |
Sector | Income / Options Overlay | Health |
52-Week High | $63.60 | $13.81 |
52-Week Low | $11.55 | $5.70 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $15.52, down 0.13% on the day, with a bearish technical outlook as moving averages signal selling pressure. The ETF's high distribution rate, exceeding 100% annualized, is a key feature but has coincided with significant NAV erosion, as noted in recent financial media. Recent weekly dividend announcements from YieldMax highlight the income focus, but underlying asset volatility remains a concern.
The outlook is cautious; while the high yield is attractive for income-seeking investors, it comes with substantial risk of principal depletion. Analyst sentiment is mixed, balancing the tactical income opportunity against structural concerns about the fund's long-term sustainability in volatile markets.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
